Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618373 | 1.00 | BLM (0.63) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL5879060 | 1.00 | BLM (0.63) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL10599018 | 1.00 | BLM (0.63) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL30866991 | 0.98 | BLM (0.61) | BLMLMNAPTPN1KDM4CKDM4A | |
| Hydrochloric Acid SCHEMBL3573141 | 0.98 | BLM (0.61) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL2172348 | 0.93 | LMNA (0.61) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL16174612 | 0.93 | LMNA (0.61) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL23673001 | 0.91 | BLM (0.59) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL230325 | 0.91 | BLM (0.59) | BLMLMNAPTPN1KDM4CKDM4A | |
| SCHEMBL23673175 | 0.91 | BLM (0.59) | BLMLMNAPTPN1KDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5626868-A | AMPHOTERIC AND NONIONIC SURFACTANTS WITH LIPID VESICLES | L'OREAL (FR) | 1997-05-06 | — | — | US | claimed |
| EP-0584315-B1 | COSMETIC AND/OR PHARMACEUTICAL COMPOSITION CONTAINING A DISPERSION OF LIPIDIC VESICLES, PROCESS FOR THE PREPARATION OF SAID DISPERSION, AND LIPIDIC VESICLE DISPERSION | OREAL (FR) | 1995-09-20 | — | — | EP | claimed |
| US-5443840-A | Aqueous dispersion phase of lipid vesicles comprising lipid phase containing ionic or nonionic amphiphilic lipid, polyol or isoprenoic acid containing phytyl chain | L'OREAL (FR) | 1995-08-22 | — | — | US | claimed |
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | FARNEX INCORPORATED (JP) | 2023-04-06 | — | — | US | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| CN-115461084-A | Non-lamellar liquid crystal forming composition with high safety | 法纳克斯株式会社 | 2022-12-09 | — | — | CN | disclosed |
| EP-4098281-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | Farnex Incorporated (JP) | 2022-12-07 | — | — | EP | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| WO-2021153635-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | 株式会社ファルネックス | 2021-08-05 | — | — | WO | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | CEVC GREGOR | 2010-04-29 | — | — | US | disclosed |
| US-20100104625-A1 | BIODEGRADABLE COMPOSITIONS AND MATERIALS | CORNELL UNIVERSITY (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT LIMITED (MT) | 2010-04-08 | — | — | US | disclosed |
| WO-2010010470-A2 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT, LTD (MT) | 2010-01-28 | — | — | WO | disclosed |
| WO-2008101173-A2 | BIODEGRADABLE COMPOSITIONS AND MATERIALS | CORNELL UNIVERSITY (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-5626868-A | AMPHOTERIC AND NONIONIC SURFACTANTS WITH LIPID VESICLES | L'OREAL (FR) | 1997-05-06 | — | — | US | disclosed |
| US-5443840-A | Aqueous dispersion phase of lipid vesicles comprising lipid phase containing ionic or nonionic amphiphilic lipid, polyol or isoprenoic acid containing phytyl chain | L'OREAL (FR) | 1995-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | DPM1, PIK3C3, NACA | BLM 4140/4885LMNA 4199/4885PTPN1 1704/4885 |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | DPM1, ERG28, NACA | BLM 4293/4885LMNA 3938/4885PTPN1 2682/4885 |
| US-20100104625-A1 | BIODEGRADABLE COMPOSITIONS AND MATERIALS | F12, CMA1, TREH | BLM 411/4885LMNA 1017/4885PTPN1 3038/4885 |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | BLM 118/4885LMNA 1444/4885PTPN1 4309/4885 |
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | LIPA, PHOSPHO1, PLA2G12A | BLM 228/4885LMNA 1087/4885PTPN1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.